Compugen Ltd CGEN posted 3.8 million in Q3 2026 revenue, completed MAIA-ovarian enrollment with data due by Q1 2027, and holds 117.5 million in cash to fund operations into 2029.
Compugen Ltd (CGEN) — Live Session & Technical Brief
Updated Nov 17, 2026 4:23 PM ET · Prev Close $2.04
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-0.98%) in Biotechnology
Compugen Ltd (CGEN) is trading within a tight intraday band at $2.02 (-0.98%, 0.82x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, CGEN is trading in line with the S&P 500 (+0.03% alpha). 14-day RSI stands at 46.9, keeping momentum in a bearish regime.
Compugen Ltd CGEN posted 3.8 million in Q3 2026 revenue, completed MAIA-ovarian enrollment with data due by Q1 2027, and holds 117.5 million in cash to fund operations into 2029.
Price ($2.02) trades relative to 20-day SMA ($2.02) and 50-day SMA ($2.18).
Market & Sector Relative Strength
CGEN trading in line with the S&P 500 (+0.03% alpha)Recent CGEN Catalyst Headlines
Verified WireCompugen Ltd. Nasdaq Cgen Tase Cgen , a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced an oral presentation at the 18th Annual Protein and Antib
Moby summary of Compugen Ltd.'s Q3 2026 earnings call
Compugen Nasdaq Cgen has completed enrollment in a randomized trial of its ovarian cancer treatment candidate COM701 and expects to report results by the end of the first quarter of 2027, executives said on the company s
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $2.02 (20-day SMA support) for directional breakout confirmation.
Technical Regime (CGEN)
MIXED MA TRENDRetail & Crowd Sentiment
QuietStockTwits messages indicate a strong bullish sentiment towards $CGEN, with buyers taking positions or adding significantly. No recent news articles were found.
About Compugen Ltd
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. …
Get Instant CGEN Catalyst Alerts
Receive an email alert when CGEN triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversCGEN Session & Catalyst FAQ
Why is CGEN stock trading near flat today?
Compugen Ltd (CGEN) is trading within a tight intraday band at $2.02 (-0.98%, 0.82x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, CGEN is trading in line with the S&P 500 (+0.03% alpha). 14-day RSI stands at 46.9, keeping momentum in a bearish regime.
Is CGEN stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.82x relative volume (low participation). Our multi-factor model currently rates CGEN as HOLD. Review full valuation, quality, and timing signals on the CGEN Buy or Sell Decision Brief →
What is CGEN's intrinsic value and expected trading range?
At $2.02, CGEN's modeled 1-to-3 session range is $1.96 – $2.08, with a key inflection level at $2.02 (20-day SMA support). Compare current price against multi-year cash flow projections in the CGEN Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for CGEN?
RSI at 46.9 reflects soft below-midline momentum. CGEN trades at $2.02 relative to its 20-day SMA ($2.02) and 50-day SMA ($2.18), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.